Progress of Circulating Tumor Cells in Cancer Management

Zhang, Chufeng; Wang, Lijie; Guan, Yan; Sun, Yulan; Liu, Xiuju; Zhu, Dongshan; Guo, Qisen

doi:10.1177/1533034615583762

Cited by 4 publications

(2 citation statements)

References 62 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor cells can leave the primary site, and enter vascular or lymphatic systems as CTCs to induce metastasis (37). CTCs can also return to the bone marrow reserve pool in a resting state; under certain conditions, CTCs can again enter the vascular or lymphatic systems, and travel to other organs to form distant metastases (38,39).…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma

et al. 2020

View full text Add to dashboard Cite

The present study aimed to investigate the clinical relevance of circulating tumor cells (CTCs) in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC), particularly in patients with nasopharyngeal and hypopharyngeal squamous cell carcinoma. CTCs were isolated using negative immunomagnetic bead enrichment and were identified by fluorescence in situ hybridization. Youden's index and the receiver operating characteristic (ROC) curve were used to select the optimal CTC baseline value. χ 2 test or Fisher's test were used to determine the association between CTC counts and clinical parameters, curative effects and prognosis. The Kaplan-Meier estimator was used to analyze overall survival (OS) and progression-free survival (PFS). In the present study, 356 peripheral blood samples (178 pretreatment samples and 178 post-treatment samples) from 178 patients were examined. The results revealed that the pretreatment CTC detection rate was 73.8%. The minimum, maximum and median CTC counts were 1, 22 and 2/3.2 ml, respectively. The number of polyploid CTCs was associated with distant metastasis (P=0.026). In addition, patients with undetectable CTCs, and decreasing or negative CTCs post-treatment tended to have a good prognosis (P<0.05). For nasopharyngeal squamous cell carcinoma, the PFS of patients with increased CTCs and CTCs ≥2/3.2 ml after treatment was significantly lower (P<0.05). For hypopharyngeal squamous cell carcinoma, it was suggested that CTCs with a cutoff value of 3 may be used to evaluate PFS and OS before and after treatment. In conclusion, CTCs may be used to monitor disease progression and the response to chemoradiotherapy for patients with LA-HNSCC. Furthermore, CTCs are a better predictor of the prognosis of hypopharyngeal squamous cell carcinoma than that of nasopharyngeal squamous cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Among these enzymes, GPX4 has a notably crucial function in ferroptosis. 97 GPX4 contains selenocysteine at its active site and functions as a phospholipid hydroperoxidase, utilizing the reducing capability of GSH to convert lipid peroxides into lipid alcohols. 98 Gpx4 is a vital gene crucial for mouse embryonic development, as its inactivation or silencing results in embryonic lethality.…”

Section: System X −mentioning

confidence: 99%

Targeting ferroptosis in gastric cancer: Strategies and opportunities

Le,

Pan,

Zhang

et al. 2023

Immunological Reviews

View full text Add to dashboard Cite

SummaryFerroptosis is a novel form of programmed cell death morphologically, genetically, and biochemically distinct from other cell death pathways and characterized by the accumulation of iron‐dependent lipid peroxides and oxidative damage. It is now understood that ferroptosis plays an essential role in various biological processes, especially in the metabolism of iron, lipids, and amino acids. Gastric cancer (GC) is a prevalent malignant tumor worldwide with low early diagnosis rates and high metastasis rates, accounting for its relatively poor prognosis. Although chemotherapy is commonly used to treat GC, drug resistance often leads to poor therapeutic outcomes. In the last several years, extensive research on ferroptosis has highlighted its significant potential in GC therapy, providing a promising strategy to address drug resistance associated with standard cancer therapies. In this review, we offer an extensive summary of the key regulatory factors related to the mechanisms underlying ferroptosis. Various inducers and inhibitors specifically targeting ferroptosis are uncovered. Additionally, we explore the prospective applications and outcomes of these agents in the field of GC therapy, emphasizing their capacity to improve the outcomes of this patient population.

show abstract